$3.46
+0.36 (+11.61%)
Open$3.22
Previous Close$3.10
Day High$3.50
Day Low$3.22
52W High$46.74
52W Low$31.95
Volume—
Avg Volume626.0K
Market Cap65.78M
P/E Ratio52.82
EPS$0.76
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,295.4% upside
Current
$3.46
$3.46
Target
$48.28
$48.28
$28.52
$48.28 avg
$57.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 35.77M | 36.63M | 30.48M |
| Net Income | -8,575,403 | -9,331,208 | -6,103,234 |
| Profit Margin | -24.0% | -25.5% | -20.0% |
| EBITDA | -11,561,063 | -12,252,085 | -10,099,093 |
| Free Cash Flow | -5,624,875 | -5,815,077 | -3,826,455 |
| Rev Growth | +23.1% | +18.9% | +13.6% |
| Debt/Equity | 0.47 | 0.46 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |